{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:25:13Z","timestamp":1793064313173,"version":"4.5.0"},"reference-count":21,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Non-ablative stereotactic body radiation therapy (SBRT) is commonly employed for locally advanced pancreatic cancer (LAPC) using computed tomography-guided radiotherapy (CTgRT) without online adaptive radiation therapy (oART). The safe delivery of ablative SBRT has been demonstrated using stereotactic magnetic resonance-guided online adaptive radiation therapy (SMART). We performed an in silico comparison of non-adapted CTgRT versus SMART to better understand the potential benefit of oART for ablative pancreatic SBRT. Methods: We retrospectively evaluated original and daily adapted SMART plans that were previously delivered for 20 consecutive LAPC cases (120 total plans across all patients) treated on a 0.35 T MR-linac prescribed to 50 Gy (gross disease) and 33 Gy (elective sites) simultaneously in five fractions. Six comparative CTgRT plans for each patient (one original, five daily treatment) were retrospectively generated with the same prescribed dose and planning parameters as the SMART plans assuming no oART availability. The impact of daily anatomic changes on CTgRT and SMART plans without oART was evaluated across each treatment day MRI scan acquired for SMART. Results: Ninety percent of cases involved the pancreatic head. No statistically significant differences were seen between CTgRT and SMART with respect to target coverage. Nearly all (96%) fractions planned on either CT or MRI platforms exceeded at least one GI organ at risk (OAR) constraint without oART. Significant differences favoring SMART over non-adaptive CTgRT were observed for the duodenum V35 Gy \u2264 0.5 cc (34.2 vs. 41.9 Gy, p = 0.0035) and duodenum V40 Gy \u2264 0.03 cc (37 vs. 52.5 Gy, p = 0.0006) constraints. Stomach V40 Gy trended towards significance favoring SMART (37 vs. 40.3 Gy, p = 0.057) while no significant differences were seen. Conclusions: This is the first study that quantifies the frequency and extent of GI OAR constraint violations that would occur during ablative five-fraction SBRT using SMART vs. CTgRT. GI OAR constraint violations are expected for most fractions without oART whereas all constraints can be achieved with oART. As such, these data suggest that oART should be required for ablative five-fraction pancreatic SBRT.<\/jats:p>","DOI":"10.3390\/cancers17132061","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:17:42Z","timestamp":1750396662000},"page":"2061","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ablative Five-Fraction CT Versus MR-Guided Stereotactic Body Radiation Therapy for Pancreatic Cancer: In Silico Evaluation of Interfraction Anatomic Changes as a Rationale for Online Adaptive Replanning"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1962-8351","authenticated-orcid":false,"given":"Adeel","family":"Kaiser","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"},{"name":"Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Luther","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Mittauer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Gul","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh K.","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Fellows","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rzepczynski","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Deere","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"},{"name":"Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6927-0402","authenticated-orcid":false,"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"},{"name":"Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nema","family":"Bassiri-Gharb","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso N.","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"},{"name":"Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Chuong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"},{"name":"Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","article-title":"Pancreatic cancer: A review of epidemiology, trend, and risk factors","volume":"27","author":"Hu","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Fu","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","article-title":"Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression","volume":"29","author":"Crane","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.phro.2019.08.002","article-title":"Multi-center evaluation of dose conformity in stereotactic body radiotherapy","volume":"11","author":"Lee","year":"2019","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_7","first-page":"16","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.ijrobp.2021.02.008","article-title":"Phase I trial of stereotactic body radiation therapy dose escalation in pancreatic cancer","volume":"110","author":"Courtney","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110064","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109869","DOI":"10.1016\/j.radonc.2023.109869","article-title":"Online adaptive radiotherapy: Assessment of planning technique and its impact on longitudinal plan quality robustness in pancreatic cancer","volume":"188","author":"Mittauer","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.radonc.2020.02.012","article-title":"Validation of an MR-guided online adaptive radiotherapy (MRgoART) program: Deformation accuracy in a heterogeneous, deformable, anthropomorphic phantom","volume":"146","author":"Mittauer","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance\u2013guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1259\/bjr\/41321492","article-title":"New developments in MRI for target volume delineation in radiotherapy","volume":"79","author":"Khoo","year":"2006","journal-title":"Br. J. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2021.11.024","article-title":"CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy","volume":"166","author":"Rodriguez","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100506","DOI":"10.1016\/j.adro.2020.06.010","article-title":"Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation","volume":"6","author":"Hassanzadeh","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101164","DOI":"10.1016\/j.adro.2022.101164","article-title":"Dose escalation for pancreas SBRT: Potential and limitations of using daily online adaptive radiation therapy and an iterative isotoxicity automated planning approach","volume":"8","author":"Rhee","year":"2023","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother. Oncol."},{"key":"ref_18","first-page":"100813","article-title":"CT-guided online adaptive stereotactic body radiotherapy for pancreas ductal adenocarcinoma: Dosimetric and initial clinical experience","volume":"48","author":"Lee","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2061\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:55:30Z","timestamp":1760032530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":21,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17132061"],"URL":"https:\/\/doi.org\/10.3390\/cancers17132061","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}